James Valentine
Board Member
Quince Therapeutics, Inc. (QNCX)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About James Valentine
James Valentine is recorded as Board Member at Quince Therapeutics, Inc. (QNCX). Quince Therapeutics, Inc. reported in an 8-K filed October 9, 2026 that James Valentine was appointed Director. Quince Therapeutics, Inc. reported in an 8-K filed October 9, 2026 that James Valentine was appointed Class I director, effective October 8, 2026. Quince Therapeutics, Inc. reported in an 8-K filed October 2, 2026 that James Valentine was appointed Class I director.
“IRulya is strengthening its Board of Directors with the following appointments:”
“James Valentine was appointed to the Board as a Class I director and as a member of the Audit Committee and as chair of the Nominating and Corporate Governance Committee of the Board; and”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2026-10-02–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Quince Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Brigette Roberts CEO, Board Member
- Christopher Lowe CEO, Board Member
- Dirk Thye, M.D. CEO, Board Member
- David A. Lamond Chairman
- Brendan Hannah CFO
- John Militello CFO, Chief Accounting Officer
- Chris Lowe COO
- Keith Fandrick COO
- Keith R. Fandrick COO
- Brigette Roberts, M.D. Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.